Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN3B | O60391 | 2/20 | 0.37 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.37 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.37 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | MET | P08581 | 11/20 | 0.33 |
| ▸ | KDR | P35968 | 7/20 | 0.33 |
| ▸ | MST1R | Q04912 | 6/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2380151 | 1.00 | GRIN3B (0.37) | GRIN3BGRIN1GRIN2CDGAT1MET | |
| SCHEMBL2377956 | 0.90 | JAK1 (0.40) | — | |
| SCHEMBL14655593 | 0.86 | GRIN3B (0.37) | GRIN3BGRIN1GRIN2CDGAT1MET | |
| SCHEMBL2380301 | 0.83 | JAK1 (0.39) | METKDRMST1R | |
| SCHEMBL2378218 | 0.82 | JAK1 (0.43) | — | |
| SCHEMBL2378972 | 0.81 | JAK1 (0.39) | — | |
| SCHEMBL17403295 | 0.79 | JAK1 (0.40) | DGAT1 | |
| SCHEMBL14655324 | 0.79 | MET (0.36) | DGAT1METKDRMST1R | |
| SCHEMBL14655557 | 0.77 | PTPN1 (0.34) | DGAT1 | |
| SCHEMBL14656033 | 0.76 | SIRT2 (0.34) | DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8518945-B2 | Pyrrolopyrazine kinase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2013-08-27 | — | — | US | disclosed |
| EP-2550273-A2 | PYRROLOPYRAZINE KINASE INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2013-01-30 | — | — | EP | disclosed |
| WO-2011117145-A2 | PYRROLOPYRAZINE KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-09-29 | — | — | WO | disclosed |
| US-20110230462-A1 | Pyrrolopyrazine Kinase Inhibitors | HENDRICKS ROBERT THAN | 2011-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230462-A1 | Pyrrolopyrazine Kinase Inhibitors | SYK, ZAP70, BTK | GRIN3B 4201/4885GRIN1 3205/4885GRIN2C 3807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.